Raymond James reinstated coverage of uniQure with an Outperform rating and $20 price target Despite having four clinical stage programs and a cash runway to year-end 2027, shares continues to trade at a negative enterprise value, notes the analyst, who adds that uniQure’s HD gene therapy, AMT-130, continues to generate “interesting data” and the company remains on track to meet with the FDA in the second half of the year to discuss regulatory requirements. “The upside potential is significant should an accelerated approval filing be on the table,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure Gains FDA Orphan Drug Status for Fabry Disease Therapy
- uniQure receives Orphan Drug Designation for AMT-191 in Fabry Disease
- uniQure treatment of Fabry disease granted orphan designation
- uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment
- uniQure announces dosing of first patient in Phase I/IIa trial of AMT-191